Jiu-Chang Zhong Selected Research

Angiotensin-Converting Enzyme 2

10/2021	Elabela prevents angiotensin II-induced apoptosis and inflammation in rat aortic adventitial fibroblasts via the activation of FGF21-ACE2 signaling.
1/2021	Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19.
10/2020	Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases.
12/2017	Apelin Is a Negative Regulator of Angiotensin II-Mediated Adverse Myocardial Remodeling and Dysfunction.
9/2017	The sirtuin 6 prevents angiotensin II-mediated myocardial fibrosis and injury by targeting AMPK-ACE2 signaling.
1/2016	Angiotensin-converting enzyme 2 ameliorates renal fibrosis by blocking the activation of mTOR/ERK signaling in apolipoprotein E-deficient mice.
8/2015	Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling.
7/2014	Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling.
9/2013	Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice.
1/2013	Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jiu-Chang Zhong Research Topics

Disease

10	Fibrosis (Cirrhosis) 06/2022 - 09/2013
8	Heart Failure 06/2022 - 01/2012
7	Inflammation (Inflammations) 01/2022 - 01/2012
7	Hypertension (High Blood Pressure) 01/2021 - 02/2005
6	Hypertrophy 06/2022 - 01/2011
5	Cardiovascular Diseases (Cardiovascular Disease) 02/2022 - 01/2017
4	Atherosclerosis 06/2022 - 01/2016
3	Myocardial Infarction 03/2021 - 11/2020
2	Vascular Remodeling 09/2020 - 07/2014
2	Heart Diseases (Heart Disease) 12/2017 - 01/2012
2	Vascular Diseases (Vascular Disease) 07/2014 - 01/2012
2	Body Weight (Weight, Body) 05/2005 - 01/2005
1	Reperfusion Injury 01/2021
1	Cardiomyopathies (Cardiomyopathy) 01/2021
1	Acute Kidney Injury (Acute Renal Failure) 01/2021
1	COVID-19 01/2021
1	Atrial Fibrillation 01/2021
1	ST Elevation Myocardial Infarction 01/2021
1	Coronary Stenosis (Coronary Artery Stenosis) 11/2020
1	Prehypertension 01/2020
1	Orthostatic Hypotension (Postural Hypotension) 05/2019
1	Ischemic Stroke 03/2018
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017
1	Obesity 01/2017
1	Cardiomegaly (Heart Hypertrophy) 09/2013
1	Vascular System Injuries 01/2012
1	Neoplasms (Cancer) 04/2010
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2010
1	Carcinoma (Carcinomatosis) 03/2010
1	Essential Hypertension 12/2004

Drug/Important Bio-Agent (IBA)

12	Angiotensin-Converting Enzyme 2IBA 10/2021 - 01/2011
8	Angiotensin IIIBA 01/2022 - 01/2012
6	ApelinIBA 02/2022 - 02/2005
6	AngiotensinsIBA 10/2020 - 02/2005
4	Proteins (Proteins, Gene)FDA Link 10/2021 - 12/2004
3	MicroRNAs (MicroRNA)IBA 02/2022 - 03/2010
3	Messenger RNA (mRNA)IBA 10/2021 - 04/2010
3	ApolipoproteinsIBA 12/2017 - 08/2015
3	CollagenIBA 09/2017 - 09/2013
3	Irbesartan FDA LinkGeneric 12/2016 - 01/2012
2	Biological ProductsIBA 01/2021 - 01/2015
2	Apelin ReceptorsIBA 11/2020 - 01/2017
2	SirtuinsIBA 10/2020 - 09/2017
2	Biomarkers (Surrogate Marker)IBA 10/2020 - 09/2020
2	Superoxides (Superoxide)IBA 12/2017 - 08/2015
2	Peptides (Polypeptides)IBA 12/2017 - 07/2014
2	Connective Tissue Growth FactorIBA 09/2017 - 09/2013
2	Apolipoproteins E (ApoE)IBA 01/2016 - 08/2015
2	Mitogen-Activated Protein Kinase 3IBA 09/2013 - 01/2011
2	Profilins (Profilin)IBA 01/2012 - 01/2011
2	Vitamin A (Retinol)FDA LinkGeneric 05/2005 - 01/2005
2	Polychlorinated Dibenzodioxins (TCDD)IBA 05/2005 - 01/2005
1	ElectrolytesIBA 06/2022
1	AcidsIBA 06/2022
1	Oxidants (Oxidizing Agents)IBA 01/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2022
1	fibroblast growth factor 21IBA 10/2021
1	omega-Chloroacetophenone (Mace)IBA 01/2021
1	Endothelin-1 (Endothelin 1)IBA 01/2021
1	dapagliflozinIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2021
1	CytokinesIBA 01/2021
1	LigandsIBA 11/2020
1	Chymosin (Rennin)IBA 10/2020
1	Antihypertensive Agents (Antihypertensives)IBA 01/2020
1	CreatinineIBA 05/2019
1	Vitamin K FDA Link 03/2018
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/2018
1	Chemokine CX3CL1IBA 09/2017
1	ChemokinesIBA 09/2017
1	apelin-13 peptideIBA 12/2016
1	salicylhydroxamic acid (SHAM)IBA 12/2016
1	angiotensin I (1-7)IBA 04/2016
1	nephrinIBA 08/2015
1	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2014
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 07/2014
1	Atrial Natriuretic Factor (ANF)IBA 09/2013
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 09/2013
1	Fibronectins (Fibronectin)IBA 09/2013
1	Matrix Metalloproteinases (MMPs)IBA 01/2013
1	Peroxynitrous Acid (Peroxynitrite)IBA 01/2012
1	JNK Mitogen-Activated Protein KinasesIBA 01/2011
1	Telmisartan (Micardis)FDA Link 01/2011
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2011
1	Small Interfering RNA (siRNA)IBA 04/2010
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 04/2010
1	Cyclin-Dependent Kinase 2IBA 04/2010
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2004

Therapy/Procedure

4	Therapeutics 03/2018 - 04/2010
3	Percutaneous Coronary Intervention 03/2021 - 11/2020
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 03/2021